Education
About Us
Working with TipRanks
Follow Us
Mark T Iwicki Insider Profile
11 Followers
Mark T Iwicki, Director at Aimmune Therapeutics, holds 258.43K shares in Kala Pharmaceuticals (Ticker: KALA), holds 9.40K shares in Akero Therapeutics (Ticker: AKRO), holds 73.58K shares in Merus (Ticker: MRUS).
Mark T Iwicki Aimmune Therapeutics (AIMT)Director
Aimmune Therapeutics (AIMT)
Director
Not Ranked
Mark T Iwicki has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Mark T Iwicki holds in companies
Most Profitable Insider Trade
Stock:
Aimmune Therapeutics
(AIMT)
(AIMT)
Rating:Informative Buy
Date:Feb 26, 2018 - Feb 26, 2019
Return:-18.20%
The most profitable trade made by Mark T Iwicki
Mark T Iwicki's Trading History
Aimmune Therapeutics
Oct 14, 2020
―
Uninformative Sell
270.48K
$0.00
Kala Pharmaceuticals
Jun 26, 2025
Director
Uninformative Sell
53.04K
$1.81M
Pulmatrix
Apr 05, 2018
Director
Uninformative Buy
―
$1.72M
Akero Therapeutics
Jun 05, 2025
Director
Uninformative Buy
―
$474.69K
Merus
Apr 17, 2023
Director
Uninformative Buy
534.68K
$4.83M
Jade Biosciences
―
Director
―
―
Third Harmonic Bio, Inc.
―
Director
―
―
Q32 Bio
―
Director
―
―
Inhibikase Therapeutics
―
CEO, Director
―
―
List of latest transactions for each holding click on a transaction to see Mark T Iwicki's performance on stock
You May Also Like
Mark T Iwicki insider profile FAQ
What is the percentage of profitable transactions made by Mark T Iwicki?
The percentage of profitable transactions made by Mark T Iwicki is ―.
What is the average return per transaction made by Mark T Iwicki?
The average return per transaction made by Mark T Iwicki is ―.
What stocks does Mark T Iwicki hold?
Mark T Iwicki holds: AIMT, KALA, PULM, AKRO, MRUS, JBIO, THRD, QTTB, IKT stocks.
What was Mark T Iwicki’s latest transaction?
Mark T Iwicki latest transaction was an Uninformative Sell of $53.04K.
What was Mark T Iwicki's most profitable transaction?
Mark T Iwicki’s most profitable transaction was an Informative Buy of AIMT stock on February 26, 2018. The return on the trade was -18.20%.
What is Mark T Iwicki's role in Aimmune Therapeutics?
Mark T Iwicki's role in Aimmune Therapeutics is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.